Spots Global Cancer Trial Database for Study of XL999 in Adults With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL999 in Adults With Solid Tumors
Official Title: A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors
Study ID: NCT00104117
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Case Western Reserve University, Univserzity Hospitals of Cleveland, Cleveland, Ohio, United States
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, United States
Contact Details
Name: Paul Woodard, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
